Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate.
Prostate brachytherapy has become an accepted treatment modality for localized prostate cancer. Long-term biochemical and biopsy data confirm the early positive impressions that brachytherapy is as valid a treatment option as radical prostatectomy or EBRT. Quality-of-life data also look promising, but more follow-up data are needed. Is brachytherapy as good as or perhaps better than radical prostatectomy? This question cannot be answered yet. Well-controlled, randomized studies are needed. In the meantime, the clinician will have to rely on the available published data.
Department of Urology, Mount Sinai School of Medicine, 1 Gastave Levy Place, New York, NY 10029, USA. nproseed@aol.com
Nelson N
NN
Stone
Richard G
RG
Stock
D000230:Adenocarcinoma / Q000532:radiotherapy*; D001918:Brachytherapy / Q000009:adverse effects; D006801:Humans; D008297:Male; D009017:Morbidity; D018579:Patient Selection; D011349:Proctitis / Q000209:etiology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000532:radiotherapy*; D011788:Quality of Life; D011879:Radiotherapy Dosage; D012984:Software; D016896:Treatment Outcome
D017430:Prostate-Specific Antigen